Medical Doctor Program year 2019 Source: CMS Open Payments, 2026 publication

Kara Steijlen

Neurology Rochester, MN Medical Doctor

NPI 1437458726 CMS profile 432767

200 1St St Sw, Rochester, MN 55905

Open in the dashboard

General payments

$0

None reported · program year 2019

Research payments

$1,591

Paid to them · 1 record reported · program year 2019

Ownership & investment interest

$0

None reported

Through program year 2019, Kara Steijlen of Rochester, MN is reported in the CMS Open Payments database as having received $0 across 0 general payments and $1,591 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 51st percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2019 Research $1,591 1

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

1,131

Median for Neurology: 833

Drug cost

$2,270,207

Median for Neurology: $202,670

Branded share of claims

18.2%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Radicava Ors Edaravone Brand 78 $1,097,272
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 20 $380,298
Relyvrio Sod Phenylbutyrat/Taurursodiol Brand 25 $326,707
Panzyga Immun Glob G(Igg)-Ifas/Glycine Brand 13 $269,567
Gammaked Immune Globul G/Gly/Iga Avg 46 Brand 26 $134,304
Riluzole Generic 144 $21,960
Lacosamide Generic 11 $9,604
Emgality Pen Galcanezumab-Gnlm Brand 11 $7,484
Baclofen Generic 79 $3,637
Duloxetine Hcl Generic 66 $3,540

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$30,497

Medicare's payments for the services billed

Medicare patients

186

Average age 70

Services billed

520

92 women, 94 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 58%
Diabetes 29%
Depression 29%
Ischemic heart disease 27%
Chronic kidney disease 19%
COPD 19%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

1 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Minnesota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2019

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record